Phase III PAOLA-1/ENGOT-OV25 Trial: Olaparib Plus Bevacizumab (BEV) As Maintenance Therapy in Patients (PTS) with Newly Diagnosed, Advanced Ovarian Cancer (OC) Treated with Platinum-Based Chemotherapy (PCH) Plus Bev

De Gregorio N, Harter P, Sehouli L, Canzler U, Marme F, Buderath P, Lueck HJ, Gropp-Meier M, Runnebaum IB, Belau A, Renner S, Schmalfeldt B, El-Balat A, Burges A, Hillemanns P, Denschlag D, Bauerschlag D, Hanker L, Schnelzer A, Ray-Coquard I (2020)


Publication Type: Conference contribution

Publication year: 2020

Journal

Publisher: KARGER

City/Town: BASEL

Pages Range: 93-93

Conference Proceedings Title: ONCOLOGY RESEARCH AND TREATMENT

DOI: 10.1093/annonc/mdz446.009

Authors with CRIS profile

Involved external institutions

How to cite

APA:

De Gregorio, N., Harter, P., Sehouli, L., Canzler, U., Marme, F., Buderath, P.,... Ray-Coquard, I. (2020). Phase III PAOLA-1/ENGOT-OV25 Trial: Olaparib Plus Bevacizumab (BEV) As Maintenance Therapy in Patients (PTS) with Newly Diagnosed, Advanced Ovarian Cancer (OC) Treated with Platinum-Based Chemotherapy (PCH) Plus Bev. In ONCOLOGY RESEARCH AND TREATMENT (pp. 93-93). BASEL: KARGER.

MLA:

De Gregorio, Nikolaus, et al. "Phase III PAOLA-1/ENGOT-OV25 Trial: Olaparib Plus Bevacizumab (BEV) As Maintenance Therapy in Patients (PTS) with Newly Diagnosed, Advanced Ovarian Cancer (OC) Treated with Platinum-Based Chemotherapy (PCH) Plus Bev." Proceedings of the ONCOLOGY RESEARCH AND TREATMENT BASEL: KARGER, 2020. 93-93.

BibTeX: Download